Web Results


Jan 13, 2016 ... v. MERCK & CO, INC., et al.,. Defendants. Case No. 5:13-cv-04057-BLF ... Merck asserts that Gilead infringes two of its patents to a certain kind ...


Parties, docket activity and news coverage of federal case Gilead Sciences, Inc. v . Merck & Co, Inc. et al, case number 5:13-cv-04057, from California Northern ...


Coverage of federal case Gilead Sciences, Inc. v. Merck & Co, Inc. et al, case number 5:13-cv-04057, from California Northern Court.


May 23, 2018 ... *Daniel Caudillo, et al. v. Merck & Co., Inc., et al. (Super. Ct. Alameda County, No. RG17857096.) Barbara Gregory, et al. v. Merck & Co., Inc., et ...


Merck Research Laboratories, Merck & Co, Inc, Whitehouse Station, .... Treatment (losartan vs placebo). 0.66 ..... Keane WF, Brenner BM, de Zeeuw D, et al.


Barry M. Brenner ... Merck & Co., Inc., West Point, Pennsylvania, USA .... Estacio et al (1998), Bakris et al (1996), ACE inhibitor vs. calcium channel antagonist].


All of these reagents have been shown to recognize l-selectin (14–17, 21–26). ... kinase activity and co-immunoprecipitation of Sos, Grb2, Shc, and l-selectin, cells ... layer chromatography polyethyleneimine-cellulose plate (Merck) with 0.75 M ..... Gulbins E, Coggeshall K M, Brenner B, Schlottmann K, Linderkamp O, Lang F.


Dec 3, 2017 ... Brenner BM, et al. "Effects of losartan on renal and ... Outcomes. Comparisons are losartan vs. placebo. ... Funding. Merck and Company ...


Apr 1, 2017 ... Clark NM, Brenner J, Johnson P, et al. Reducing disparities in diabetes: the alliance model for health care improvements. Diabetes Spectr 2011 ...